Ascelia Pharma
Biotechnology company developing and commercializing novel drugs for orphan oncology.
ACE | ST
Overview
Corporate Details
- ISIN(s):
- SE0010573113 (+2 more)
- LEI:
- 5493002YR9VCJJPWYN08
- Country:
- Sweden
- Address:
- Hyllie Boulevard 34, 215 32 Malmö
- Website:
- https://www.ascelia.com/
- Sector:
- Manufacturing
Description
Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-04-03 08:45 |
NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB
|
English | 341.9 KB | ||
| 2020-04-01 17:15 |
Correction to press release regarding in change in number of shares and votes i…
|
English | 167.5 KB | ||
| 2020-04-01 17:15 |
Korrektion till pressmeddelande om ändring av antalet aktier och röster i Ascel…
|
Swedish | 169.4 KB | ||
| 2020-03-31 20:15 |
Ändring av antalet aktier och röster i Ascelia Pharma AB
|
Swedish | 170.7 KB | ||
| 2020-03-31 20:15 |
Change in number of shares and votes in Ascelia Pharma AB
|
English | 171.2 KB | ||
| 2020-03-02 17:00 |
Nyemission och återköp av C-aktier för aktiesparprogram
|
Swedish | 124.4 KB | ||
| 2020-03-02 17:00 |
Issue and repurchase of series C shares for share saving program
|
English | 126.4 KB | ||
| 2020-02-19 18:30 |
First patient enrolled in pivotal Phase III clinical study SPARKLE with lead ca…
|
English | 190.3 KB | ||
| 2020-02-19 18:30 |
Första patienten rekryterad till den registreringsgrundande kliniska fas III-st…
|
Swedish | 188.5 KB | ||
| 2020-02-14 08:00 | Swedish | 1.2 MB | |||
| 2020-02-14 08:00 | English | 1.1 MB | |||
| 2020-01-27 09:22 | English | 33.7 KB | |||
| 2020-01-13 15:30 |
Five sites now opened in the pivotal Phase III clinical study SPARKLE for lead …
|
English | 182.3 KB | ||
| 2020-01-13 15:30 |
Fem kliniker är nu öppnade till den registreringsgrundande kliniska fas III-stu…
|
Swedish | 179.6 KB | ||
| 2019-12-18 09:30 |
Nomination Committee appointed for AGM 2020 in Ascelia Pharma AB
|
English | 194.3 KB |
Automate Your Workflow. Get a real-time feed of all Ascelia Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Ascelia Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Ascelia Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-22 | Marie Birgitta Källström | Other | Other | 18,752 | 40,316.80 SEK |
| 2025-04-15 | Niels Mengel | Other | Other | 92,304 | 198,453.60 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 50,000 | 107,500.00 SEK |
| 2025-04-15 | Carin Linde | Other | Other | 40,328 | 86,705.20 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 21,688 | 46,629.20 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 20,472 | 44,014.80 SEK |
| 2025-04-15 | Julie Brogren | Other | Other | 18,000 | 38,700.00 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 6,152 | 13,226.80 SEK |
| 2024-09-03 | KIBEGEON | Other | Sell | 913,545 | 150,917.63 SEK |
| 2024-09-03 | Niels Mengel | Other | Sell | 131,965 | 17,815.28 SEK |
Peer Companies
